onychomycosis
Conditions
Interventions
Observation group:Oral terbinafine hydrochloride
Sponsors
Chongqing Public Health Medical Center
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) Male or female adults >= 18 years of age. (2) People living with HIV who are on a stable ART regimen (same prescription) for at least 6 months (3) Naive onychomycosis patients who are prescribed oral terbinafine treatment and who have not received any antifungal treatment in the past 3 months.
Exclusion criteria
Exclusion criteria: (1) Included in other clinical studies (except non-interventional studies) in the past 6 months; (2) Serious cardiovascular and cerebrovascular diseases, liver and kidney diseases, diabetes, blood diseases, autoimmune diseases, severe malnutrition. (3) Intestinal diseases: acute and chronic enteritis, ulcerative colitis, Crohn's disease, irritable bowel syndrome; (4) Taken drugs that have significant influence on the intestinal barrier, such as metformin, probiotics and prebiotics, in the past 4 weeks; (5) Received enteroscopy in the last 4 weeks; (6) Known Allergy to terbinafine or equivalent medication; (7) Other factors that may have significant influence on the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma(1?3)-ß-D-glucan;Plasma intestinal fatty acid binding protein;Plasma 3a regenerating islet-derived protein-3a,;Microbiota composition;mycobiota composition;Plasma Lipopolysaccharide; | — |
Countries
China
Contacts
Public ContactJing Ouyang
Chongqing Public Health Medical Center
Outcome results
None listed